LAT CAB (2021-present)
Funded by the Unitaid LONGEVITY project, the LAT CAB is a new cross-disease long-acting technologies (LAT) community advisory board focused on malaria, the hepatitis C virus, HIV, and latent TB infection.
Materials in this section
Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments
A survey sought to understand the acceptability of approaches to long-acting HCV treatment. More
Call for New Global Long-Acting Technologies CAB Members from Asian, Central African, Eastern European, MENA, and Latin American Countries
TAG and AfroCAB announce an expanded call for a new cross-disease LAT CAB focused on malaria, hepatitis C, and latent TB. Apply now! Applications accepted on a rolling basis. More
Hepatitis C and TB Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access
A patent landscape, released by TAG, investigates potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines. More
TAGline: Delivering on the Promise of Long-Acting Formulations
October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria. More
Medicines Patent Pool Secures its First Licence on Promising Long-Acting Technologies for Malaria, TB, and Hepatitis C
The licence covers the patents and expertise of promising long-acting injectable technologies that could be applied in three disease areas with a high prevalence in LMICs. More
Illustrated Glossary for LATs
The Glossary compiles frequent terms and concepts used in the research and development of long-acting technologies. More
